Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexinidazole for gambiense human African trypanosomiasis at any stage
PACTR201704002215604Recruiting
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Fexinidazole in African trypanosomiasis (HAT) (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Success or failure for patients any stage HAT. Started Nov 2016; status: recruiting.
02
Drugs
Fexinidazole
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on PACTR201704002215604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201704002215604.